Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy

Table 3 Summarize the limitations of current clinical trials and propose solutions

Limitations	Solution
Most clinical trials do not take into account the etiology of HCC	Subgroup analysis according on real-world causes
Insufficient exploratory analysis of subgroups during safety evaluation	Further analysis will be performed based on the subject's characteristics (e.g., height, weight, underlying disease) or the subject's population (e.g., sex, age)
The sample size of some studies was too small and easy to shift the results	Strict adherence to the inclusion and exclusion criteria, increasing the sample size
Assessing QOL after treatment could help assess the negative impact and clinical decisions of appropriate treatment, but the primary endpoint of most experiments does not include QOL	The primary endpoint, in addition to tumor treatment response and imaging assessment

HCC: Hepatocellular carcinoma; QOL: Quality of life.